Experimental human challenge infections can accelerate clinical malaria vaccine development
Experimental human challenge infections can accelerate clinical malaria vaccine development
复制标题
DOI：
10.1038/nri2902
复制
发表时间：
2011-01-01
影响因子：
100.3
通讯作者：
Moorthy, Vasee S.
中科院分区：
文献类型：
--
作者：
Sauerwein, Robert W.;Roestenberg, Meta;Moorthy, Vasee S.
疟疾是全世界最常见的传染病之一，每年有近100万人死亡，估计有2.43亿临床病例。几种候选疟疾疫苗已经进入第二阶段临床试验，但结果往往令人失望。作为这些第二阶段现场试验的替代方案，候选疟疾疫苗的效力可以首先通过参与者故意接触感染性蚊子叮咬(子孢子挑战)或血期寄生虫接种(血期挑战)来评估。随着越来越多的疟疾候选疫苗被开发出来，人类疟疾挑战模型是否应该被更广泛地使用，以减少成本和时间投入？本文回顾了以往在子孢子期和血液期人类疟疾挑战模型方面的经验，并对这些模型在疟疾疫苗开发中的未来前景进行了展望。
Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1 million deaths and an estimated 243 million clinical cases annually. Several candidate malaria vaccines have reached Phase IIb clinical trials, but results have often been disappointing. As an alternative to these Phase IIb field trials, the efficacy of candidate malaria vaccines can first be assessed through the deliberate exposure of participants to the bites of infectious mosquitoes (sporozoite challenge) or to an inoculum of blood-stage parasites (blood-stage challenge). With an increasing number of malaria vaccine candidates being developed, should human malaria challenge models be more widely used to reduce cost and time investments? This article reviews previous experience with both the sporozoite and blood-stage human malaria challenge models and provides future perspectives for these models in malaria vaccine development.